相关实验视频

Updated: Jun 30, 2025

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

Published on: May 31, 2016

SNF472:一种用于血管化和化作用的新型治疗剂

Canlin Yang¹, Zhiyuan Wei¹, Wen Shi¹

¹Department of Nephrology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.

Journal of nephrology

|March 21, 2024

概括

慢性病 (CKD) 的血管化存在严重风险. 新型抑制剂SNF472在阻断晶体形成和沉积方面表现有前途,提供了一种新的治疗途径.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
心血管医学心血管医学
药理学药理学是指药理学的学科.

背景情况:

血管化是慢性病 (CKD) 的普遍并发症,显著增加心血管事件风险和死亡率.
一种严重的表现,即囊症,会影响患有晚期功能障碍或透析患者.
目前对CKD血管化的治疗方法有限,并专注于风险因素管理.

研究的目的:

审查新型血管化抑制剂SNF472的作用机制,疗效和安全性.
提供SNF472在CKD患者的潜在治疗作用的全面概述.
总结正在进行的评估SNF472.2.的临床研究.

主要方法:

对SNF47的临床前和临床研究的综述2.
对SNF472直接抑制和晶体形成的分析.
评估来自第三阶段临床试验的数据.

主要成果:

SNF472 (myo-inositol hexaphosphate) 通过阻断晶体形成和沉积,直接抑制子宫外化.
最近的临床研究证实了SNF472在抑制血管化的有效性和安全性.
目前,SNF472正在进行 Vascular Calcification 治疗的第三阶段临床试验.

结论:

在CKD中,SNF472代表了一种有前途的新型治疗剂,用于血管化.
进一步的临床研究至关重要,以确认其长期益处和安全性.
在CKD管理方面,SNF472可能会提供一种新的治疗策略,以满足严重的未满足需求.

关键词:

这是一个calciphylaxis.慢性脏疾病慢性脏疾病在SNF472中使用.治疗方法治疗方法血管化是因为血管化.

更多相关视频

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro

Published on: June 2, 2022

Author Spotlight: Enhanced Quantification of Cardiovascular Calcification Progression for Longitudinal Micro PET/CT Studies in Small Research Animals

Author Spotlight: Enhanced Quantification of Cardiovascular Calcification Progression for Longitudinal Micro PET/CT Studies in Small Research Animals

Published on: November 15, 2024

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...